TQB-2928

N/A

Report date: 2024/07/05 11:40:53

Base Information

Drug NameTQB-2928
Drug Alias NameTQB-2928
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCluster of differentiation 47 inhibitorsMacrophages inhibitorsSignal-regulatory protein alpha inhibitors
TargetsCluster of differentiation 47Signal-regulatory protein alpha
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungLeukemia, Myeloid, Acute
Inactive IndicationsSolid tumoursHematologic NeoplasmsOsteosarcoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A